Innate Pharma S.A. is a clinical-stage biotechnology company founded in October 1999 in Marseille, France, by scientific pioneers including Jean-Jacques Fournié, Eric Vivier, and Marc Bonneville. The enterprise was established with the core vision of harnessing innate immunity—specifically focusing on natural killer (NK) cells—to pioneer innovative immunotherapies for cancer. Over the decades, Innate Pharma expanded its scientific capabilities from early academic research into advanced antibody engineering, completing its initial public offering on Euronext Paris in 2006 and later establishing a dual-listing presence on the Nasdaq market in the United States. Along its corporate trajectory, the company forged major strategic licensing alliances and co-development partnerships with leading global pharmaceutical giants, including AstraZeneca, Sanofi, Bristol-Myers Squibb, and Sobi, advancing a diverse pipeline of therapeutic antibodies, antibody-drug conjugates, and multi-specific NK cell engagers designed to address areas of high unmet medical need in oncology.